Updates from Syncona and our portfolio companies
Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy
An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.
Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview
Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt explain how Syncona has built a globally leading platform of unpartnered gene therapy assets.
Syncona’s Chief Investment Officer, Chris Hollowood and Syncona Partner, Dominic Schmidt, provide an introduction to gene therapy, a field where Syncona has developed deep domain expertise and built a strategic platform.
Syncona speaks to one of Quell Therapeutics’ academic founders, Alberto Sanchez-Fueyo, about his career, the potential of T-regulatory cells and his vision for the business.